Article Per Year (5 Year)
p-Index From 2020 - 2025
0.702
P-Index
This Author published in this journals
All Journal International Journal of Public Health Science (IJPHS) Cermin Dunia Kedokteran Asian Journal of Health Research
Probo Yudha Pratama Putra
Medical Faculty, University Of Muhammadiyah Malang
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Colchicine as adjuvant therapy in COVID-19 patients: A meta-analysis Betty Rachma; Probo Yudha Pratama Putra; Zakiya Zulaifah; Arlinda Silva Prameswari; Dinda Amalia Eka Putri
International Journal of Public Health Science (IJPHS) Vol 11, No 4: December 2022
Publisher : Intelektual Pustaka Media Utama

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11591/ijphs.v11i4.21837

Abstract

SARS CoV-2 infection results in hyperinflammatory responses through the activation of proinflammatory cytokines and chemokines. Colchicine is an anti-inflammatory drug that reduces superoxide production, TNF-a activation, and neutrophil chemotaxis. This study aims to determine the effect of adjuvant colchicine on mortality in COVID-19 patients. Systematic literature searching was conducted on PubMed, ScienceDirect, Cochrane Library, and medRxiv with keywords colchicine, Coronavirus Disease, COVID-19, SARS CoV-2, and mortality. Five randomized controlled studies with 15.779 patients were included. There was no significant difference between colchicine group and standard group (OR 1.00 [95% CI 0.91-1.09], p=0.94), Invasive mechanical ventilation necessity also did not show significant difference (OR 0.99 [95% CI 0.83-1.17 p=0.88). There was no significant difference in the incidence of cardiovascular disease (OR 1.11 [95% CI 0.50-2.46], p = 0.79), also the incidence of pneumonia was lower in colchicine group (OR 0.68 [95% CI 0.49-0.93], p=0.02), while the incidence of gastrointestinal complaints was higher in colchicine group (OR 2.09 [95% CI 1.84-2.37], p<0.00001). Colchicine as COVID-19 adjuvant therapy did not significantly reduce mortality, the need for invasive mechanical ventilation, and the incidence of cardiovascular disease. Furthermore, the colchicine group had lower pneumonia incidence and higher gastrointestinal complaints incidence.
Mortality and morbidity of pregnant woman with COVID- 19 Infection : A meta analysis Aida Musyarrofah; Anung Putri Illahika; Probo Yudha Pratama Putra; Dinda Amalia Eka Putri; S.Khansa Zatalini; Yohanes Eddy Prasetyo
International Journal of Public Health Science (IJPHS) Vol 11, No 4: December 2022
Publisher : Intelektual Pustaka Media Utama

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11591/ijphs.v11i4.21769

Abstract

Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and declared as a global pandemic in March 2020. There is a special immune tolerance in pregnant woman, predisposes to a viral infection, then increased risk severe complication. A comprehensive literature study was performed in July 2021 through Science Direct, Cochrane, and PubMed, with keywords “COVID-19”, “SARS-CoV-2”, “Pregnancy”, “Pregnant”, and “Complication”. Nine studies with 30.257 infected patients and 1.678.974 non infected patients were included. The data show that preterm birth (OR=1.43, 95% CI: 1.17-1.74; p = 0.0004, I2=90%) less in non infected groups, no camparable finding in vaginal delivery (OR =0.93, 95% CI: 0.82-1.06; p<0.030, I2=75%) and caesarian delivery (OR =1.07, 95% CI: 0.90-1.28; p<0.045, I2=96%). ICU admission reported high percentage in infected patients (OR =4.87, 95% CI: 3.08-7.71; p<0.0001, I2=93%), we found that obstetric complication in subgroup (OR =1.31, 95% CI: 0.13-1.52; p<0.0003,I2=54%) and mortality (OR =17.41, 95% CI: 11.04-27.46; p<0.0001, I2=0%) less in non infected patients. Pregnancy with infected COVID-19 has high percentage of mortality and morbidity events. Infected and non infected patients has equal chance for vaginal or caesarian delivery.
Case Report: Generalize Pustular Psoriasis Pregnancy (GPPP) in Multiple Pregnancies Aida Musyarrofah; Probo Yudha Pratama Putra; Dwi Nurwulan Pravitasari; Yulia Nugrahanitya
Asian Journal of Health Research Vol. 1 No. 3 (2022): Volume 1 No 3 (December) 2022
Publisher : Ikatan Dokter Indonesia Wilayah Jawa Timur

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55561/ajhr.v1i3.34

Abstract

Introduction: General Pustular psoriasis pregnancy (GPPP) is a dermatosis that occurs in pregnancy and requires serious management to reduce the risk of mortality and morbidity in both pregnancy mother and fetus. This disorder is also called impetigo herpetiform. Case Presentation: We report a woman with multiple pregnancies, G3P2A0 at 21 weeks gestation, with well-defined erythematous macules 5–10 cm in diameter, partly coalescent, with thick scales, and 0.1–0.2 cm diameter pustules and leukocytosis. Patients receive 1 mg of dexamethasone every morning, clobetasol cream 0.05% twice daily, gentamycin 0.1% three times daily, and 3% salicylic acid cream, while to avoid the emergence of preeclampsia aspirin is given at a low dose of 75 mg/day, and we use vipalbumin to treat hypoalbuminemia. The patient gave birth to premature twins by normal delivery. Conclusion: GPPP is a rare dermatosis with serious risks and consequences for both mother and child. Supportive management is needed to maintain pregnancy and prevent complications.
Perbandingan Efektivitas dan Keamanan Early dengan Delayed Kolesistektomi Laparoskopik untuk Kolesistitis Akut: Systematic Review dan Meta-Analisis dari 18 RCT Farizky Jati Ananto; Andi Abdillah; Probo Yudha Pratama Putra; Eko Setyo Herwanto
Cermin Dunia Kedokteran Vol. 49 No. 8 (2022): Dermatologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v49i8.289

Abstract

Pendahuluan. Secara teoritis, pada tata laksana kolesistitis akut, kolesistektomi laparoskopik lebih menguntungkan dibandingkan kolesistektomi konvensional. Namun, masih terdapat perdebatan mengenai perbedaan efektivitas dan keamanan antara early laparoscopic cholecystectomy (ELC) dengan delayed laparoscopic cholecystectomy (DLC). Metode: Meta-analisis evidence based dibuat pada November 2019 untuk menilai dan membandingkan efektivitas dan keamanan dari keduanya, menggunakan artikel di PubMed, Science Direct, Cochrane Library, ClinicalTrial.gov, dan Research Gate. Prosedur meta-analisis sesuai diagram dan alur PRISMA guideline, dilakukan dan diolah dengan program RevMan V.5.3. Hasil: Total 1.010 kasus ELC dan 1.072 kasus DLC dari 18 penelitian. Didapatkan perbedaan yang signifikan pada total lama perawatan di rumah sakit (MD 3,27 hari; 95% CI –4,32 hingga –2,23; p < 0,00001). Tidak didapatkan perbedaan signifikan pada durasi operasi (MD 8,36 menit; 95 % CI –0,15 hingga 16,88; p = 0,05) dan konversi menjadi operasi terbuka (RR 0,97; 95% CI 0,77 hingga 1,22; p = 0,80). Untuk komplikasi kebocoran bilier (OR 1,23; 95% CI 0,71 hingga 2,14; p = 0,46), perforasi kandung empedu (OR 1,14; 95% CI 0,64 hingga 2,06; p = 0,65), dan infeksi luka pasca-operasi (OR 0,99; 95% CI 0,60 hingga 1,63; p = 0,96) tidak didapatkan perbedaan signifikan. Hanya injuri duktus bilier yang memiliki perbedaan signifikan (OR 0,34; 95% CI 0,15 hingga 0,78; p = 0,01) Simpulan: Untuk tata laksana kolesistitis akut, ELC memiliki efektivitas dan keamanan lebih baik dibandingkan DLC ditinjau dari total lama perawatan di rumah sakit dan injuri duktus bilier. Introduction: Theoretically, in the management of acute cholecystitis, laparoscopic cholecystectomy has advantages compared to conventional cholecystectomy. However, there is still discussion on the appropriate timing of laparascopic cholecystectomy. Meta-analysis was made on the effectiveness and safety of early laparoscopic cholecystectomy (ELC) compared to delayed laparoscopic cholecystectomy (DLC). Method: A systematic review and meta-analysis was conducted in November 2019 from PubMed, Science Direct, Cochrane Library, ClinicalTrial.gov, and Research Gate to compare the effectiveness and safety of both treatments. The meta-analysis procedure was in accordance with the PRISMA flow and diagram guidelines, and processed with the RevMan V.5.3 program. Results: A total of 1010 ELC cases and 1072 DLC cases from 18 studies were included. Significant difference was found in total duration of hospital stay (MD –3.27 days, 95% CI –4.32 to –2.23, p <0.00001). No significant difference was found for operation time (MD 8.36 minutes, 95% CI –0.15 to 16.88, p = 0.05) and conversion to open surgery (RR 0.97, 95% CI 0.77 to 1.22, p = 0.80). No significant difference was found for complications such as bile leakage (OR 1.23, 95% CI 0.71 to 2.14, p = 0.46), gallbladder perforation (OR 1.14, 95% CI 0.64 to 2.06, p = 0.65), and wound infection (OR 0.99, 95 % CI 0.60 to 1.63, p = 0.96). The only significant difference was found in bile duct injury complication (OR 0.34, 95% CI 0.15 to 0.78, p = 0.01). Conclusion: In the management of acute cholecystitis, ELC has better effectiveness and safety compared to DLC in terms of total hospital stay and bile duct injury.
Co-Authors Aida Musyarrofah Andi Abdillah Anung Putri Illahika Arlinda Silva Prameswari Betty Rachma Dinda Amalia Eka Putri Dinda Amalia Eka Putri Dwi Nurwulan Pravitasari Eko Setyo Herwanto Farizky Jati Ananto S.Khansa Zatalini Yohanes Eddy Prasetyo Yulia Nugrahanitya Zakiya Zulaifah